VEGFR2/CD309 antibody
Quick Overview for VEGFR2/CD309 antibody (ABIN7120750)
Target
See all VEGFR2/CD309 (VEGFR2) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purification
- Immunogen affinity purified
-
Purity
- ≥95 % as determined by SDS-PAGE
-
Immunogen
- Vascular endothelial growth factor receptor 2
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB: 1:500-1:1000, IHC: 1:50-1:500
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
-
Expiry Date
- 12 months
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Alternative Name
- VEGFR2
-
Background
- Synonyms:CD309, Fetal liver kinase 1, FLK 1, FLK1, KDR, Kinase insert domain receptor, VEGF Receptor 2, VEGFR, VEGFR 2, VEGFR2 Background:KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.
-
Molecular Weight
- 200 kDa
-
Gene ID
- 3791
-
UniProt
- P35968
-
Pathways
- RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Target
-